Noelia Tarazona, Research Fellow at Mass General Brigham Cancer Center, shared a post on LinkedIn about a recent article by Pablo Tolosa et al, published in Med:
“The SERENA-6 trial shows that acting before radiologic progression can matter.
Switching to camizestrant upon emerging ESR1 mutations in ctDNA extended PFS and delayed QoL decline in HR+/HER2-Breast Cancer.
A step closer to real-time, biology-driven care.”
Title: Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2– breast cancer
Authors: Pablo Tolosa, Juan Montes, Eva Ciruelos
Read the Full Article on Med
More posts featuring Noelia Tarazona.